Venture capital firm Eclipse and the Mayo Clinic are creating and providing seed funding for a new company called Nucleus RadioPharma that aims to provide cancer patients access to therapeutic radiopharmaceuticals.
Nucleus RadioPharma said it plans to develop technologies to modernize the clinical development, manufacturing, and supply chain of new radiopharmaceutical-based therapies.
The new company will be headed by CEO Charles Conroy. Before joining Nucleus, Conroy served as the CEO of ARTMS, a provider of technologies for radiopharmaceutical production.
The founding board of directors comprises the following individuals:
- Manu Nair, chair of corporate development at the Mayo Clinic
- Justin Butler, partner at Eclipse
- Mary Kate Wold, CEO and president of the Church Pension Group and a former senior executive at Wyeth
- Dr. Ned Sharpless, former director of the U.S. National Cancer Institute and former acting commissioner of the U.S. Food and Drug Administration
- Mike Rossi, former head of radioligand therapy and imaging at Novartis
